Mutations in the Wilm's tumor 1 (WT1) gene are associated with a wide spectrum of renal manifestations, ultimately leading to end-stage kidney failure. There is an inadequate understanding of the molecular functions of WT1 in renal development, and this has limited the potential for therapeutic interventions in WT1-related diseases. In this review we discuss the existing data on the genetic and epigenetic abnormalities that have been described in WTs and their potential utility as biomarkers for risk stratification, prediction and prognosis in patients withWTs. This article is protected by copyright. All rights reserved.
Journal of cellular physiology. 2017 May 20 [Epub ahead of print]
Afsane Bahrami, Marjan Joodi, Mina Maftooh, Gordon A Ferns, Mehrdad Ahmadi, Seyed Mahdi Hassanian, Amir Avan
Department of Modern Sciences and Technologies; Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Department of Pediatric Surgery, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad, Iran., Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK.